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a-Latrotoxin is a potent stimulator of neurotransmitter release from nerve terminals. High affinity membrane cl-latrotoxin receptor was purified 
in an active binding form. It is a membrane glycoprotein (M, 160,00~220,000) which may be complexed to a smaller polypeptide (M, 29,000). 
The structure of the receptor protein suggests that it may be a synapse-specific cell recognition molecule. Intracellularly, the tx-latrotoxin receptor 
interacts with synaptotagmin, a calcium- and phospholipid-binding protein specifically localized in the synaptic vesicle membrane. This interaction 
may be important for targeting of synaptic vesicles to presynaptic release sites. 
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1. INTRODUCTION 
The major function of the nerve system is to perceive, 
process and output signals which control the functions 
of an organism. This is achieved by specific and very 
complex signaling between neuronal cells. To communi- 
cate, neurons form close contacts (called synapses) 
where low molecular weight neurotransmitters are re- 
leased from the nerve terminal of a presynaptic neuron 
and received by the postsynaptic membrane of another 
cell. Neurotransmitters are accumulated and stored in 
specific cell organelles, synaptic vesicles. In the course 
of neuronal signal transduction the presynaptic mem- 
brane is depolarized and calcium channels are activated, 
which results in a calcium influx and subsequent exocy- 
tosis of synaptic vesicles. The physiology and pharma- 
cology of neurotransmitter release was characterized in 
details but not until now have we started to understand 
what are the molecular mechanisms which underlie this 
phenomenon (for recent reviews see [l-5]). 
One of the approaches which appears to be especially 
useful in the studies of different neural functions is the 
use of natural neurotoxins as tools to identify and char- 
acterize their target molecules. Several neurotoxins are 
known to influence nerve terminal function. Botulinum 
and tetanus toxins block neurosecretion by a selective 
Correspondence address: A. Petrenko, Howard Hughes Medical Insti- 
tute, 5323 Harry Hines Blvd., Dallas, TX 752359050, USA. Fax: (1) 
(214) 689 5066. 
Published by Elsewer Science Publishers B. K 81 
proteolysis of a synaptic vesicle protein [6]. a-Latro- 
toxin is a well-characterized universal stimulator of syn- 
aptic vesicle exocytosis and neurotransmitter release [7] 
which has been extensively employed in physiological 
studies of neurosecretion. It has been particularly useful 
in establishing the vesicular theory of neurotransmitter 
release [8,9]. The molecular mechanism of the a-latro- 
toxin action is not clear yet. However, it was found to 
include binding initially to a receptor protein which is 
localized exclusively in the presynaptic membrane [lo]. 
The scope of this review is to summarize the most recent 
findings of the a-latrotoxin studies focusing to the char- 
acteristics of the membrane-bound a-latrotoxin recep- 
tor. 
2. a-LATROTOXIN: THE MODE OF ACTION 
a-Latrotoxin (M, 116,000 Da) is one of the major 
protein components of black widow spider venom 
which is selectively toxic to vertebrates [l 11. This toxin 
has been purified either by a combination of gel filtra- 
tion and ion-exchange chromatography [11,12], or by 
immunoaffinity chromatography [131. 
The physiological action of the cc-latrotoxin is charac- 
terized by the following features: 
1. Upon a-latrotoxin stimulation, the number of neuro- 
transmitter quanta released correlates with the number 
of synaptic vesicles exocytosed, indicating that toxin- 
stimulated neurotransmitter release occurs via exocyto- 
sis [14]. 
2. Stimulation by toxin results in the exclusive release 
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of small synaptic vesicles whereas the neuropeptide con- 
taining large dense core vesicles are not involved [ 151. 
3. a-Latrotoxin was found to be an effective secretion 
stimulator for all types of neurotransmitters (reviewed 
in [7]), thus its action should be targeted to the machin- 
ery, which is similar in the synapses of different types. 
4. In comparison with physiological depolarization- 
driven release, a-latrotoxin stimulates the exocytosis of 
a much wider (probably all available) pool of synaptic 
vesicles [ 161. Interestingly, under these conditions the 
proteins of synaptic vesicles get incorporated into the 
presynaptic membrane but do not intermix with its pro- 
tein components [17,18]. 
5. Along with synaptic vesicle exocytosis, a-latrotoxin 
depolarizes the presynaptic membrane and causes an 
influx of Ca” ions, even in the presence of calcium 
channel antagonists, by induction of different channels 
[ 191. Generally, the function of ol-latrotoxin does not 
require extracellular Ca2+ provided that Mg2’ or an- 
other divalent cation is present [14,20]. It was also re- 
ported recently, that the effect of the toxin has both 
external Na’-dependent and independent components 
WI. 
In artificial membranes, ol-latrotoxin can form cati- 
onic channels [22,23]. However, the properties of these 
channels are different from those induced in the presyn- 
aptic membrane [24]. A monoclonal anti-a-latrotoxin 
antibody which impairs the toxin stimulatory action but 
does not influence its binding to the receptor, also inhib- 
its toxin-induced channels in artificial membranes [25]. 
Surprisingly, there is no homology of a-latrotoxin [26] 
with any known ion channel protein. However, a low- 
molecular weight protein which may be an ionophore, 
has been found in the toxin preparations [27]. 
a-Latrotoxin was also reported to induce the fusion 
of liposomes with the lipid bilayer when applied from 
the opposite side [28]. Thus, there is a possibility that 
after binding to its receptor, the toxin (or at least a part 
of the molecule) is translocated through the membrane, 
which results not only in channel formation, but also in 
the interaction with the synaptic vesicle membrane. It 
was also proposed that ol-latrotoxin is translocated into 
the cytosol, and its domain containing twenty CDClO 
(or ankyrin) repeats interacts with intracellular target 
1291. 
3. IDENTIFICATION AND MOLECULAR CLON- 
ING OF THE a-LATROTOXIN RECEPTOR 
The iodinated radioactive derivative of ol-latrotoxin 
was used to identify high-affinity receptors in nerve tis- 
sues and also in differentiated PC12 cells [30-321. The 
parallel studies of toxin binding and its stimulator-y ac- 
tivity suggested that the function of a-latrotoxin re- 
quires binding to a specific cell surface receptor as an 
initial step [31]. Measuring toxin binding at different 
temperatures, two types of binding sites were detected 
in rat brain synaptosomes [33]. It was proposed that, 
depending on membrane fluidity, a-latrotoxin may 
complex with one or two receptor molecules [33]. 
An immunofluorescence study of the neuromuscular 
junction indicated that the a-latrotoxin receptor is lo- 
calized exclusively in the presynaptic membrane [lo]. 
This was also supported by a quantitative comparison 
of the receptor and synapsin distribution in brain [34]. 
Since the a-latrotoxin receptor appears to be a specific 
marker of the nerve terminal membrane, it is a very 
attractive target for further structural and functional 
studies. 
An affinity chromatography approach was success- 
fully utilized to purify the a-latrotoxin receptor [35-371. 
Rat or bovine membranes were solubilized with Triton 
X- 100 and the extract was applied to an agarose column 
containing immobilized a-latrotoxin. The eluted pro- 
teins exhibited a specific high-affinity toxin binding 
comparable to that of the membrane receptor (& close 
to 10m9 M) [35-371. The receptor activity can be de- 
stroyed by proteases, denaturing agents, heating, and it 
is also partially inhibited by lectins [37], which agrees 
with the lectin antagonism to the toxin stimulatory ac- 
tivity [38]. However, the purified receptor as well as the 
solubilized one bind a-latrotoxin only in the presence of 
calcium [35,37], whereas the membrane receptor binds 
toxin even in the presence of EDTA [32,33,37]. After 
reconstitution in liposomes, the affinity-purified recep- 
tor does not require Ca 2+ for toxin binding and is capa- 
ble to form cation channels upon the addition of a- 
latrotoxin [39]. 
Currently, the a-latrotoxin receptor is thought to be 
composed of a protein which is a member of a family 
of highly homologous polypeptides ranging in size from 
160,000 to 220,000 Da. These may be complexed with 
a smaller protein of M, 29,000 Da. This conclusion is 
supported by the following lines of evidence: 
1. Electrophoretic analysis detects 200K, 160K and 29K 
polypeptides as the major protein components in the 
affinity-purified receptor preparations [36,37,40,41]. 
2. In a sucrose density sedimentation experiment, the 
distribution of 160K and 200K proteins correlates 
strongly with the profile of the specific a-latrotoxin- 
binding activity. The sedimentation pattern of the 29K 
protein suggests that it may form a complex with either 
the 160K or the 200K protein and that its presence is 
not absolutely necessary for the toxin binding. When a 
mixture of toxin and receptor is sedimented, all three 
polypeptides as well as the toxin shift to a higher molec- 
ular mass, indicating the formation of stable complexes 
[401* 
3. The 160K and 200K proteins can be separated by 
anion-exchange chromatography. After separation, 
both of these retain their high affinity a-latrotoxin bind- 
ing [37] and can complex with the 29K protein [40]. 
4. An antibody, which stains both the 200K and 160K 
proteins on Western blots, also immunoprecipitates the 
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Fig. 1. Domain structure of the a-latrotoxin receptor (deduced from the neurexin Ia cDNA). The protein is shown as bar diagram with amino 
terminus on the left. The matching peptide sequences derived from the affiity-purified receptor are outlined as solid bars. The signal peptide (SP) 
is followed by three repeats (A, B and C), each containing a central EGF-domain. Left and right arms (Ga and Gb) of each repeat are homologous 
to the laminin A G-domain repeats. The single transmembrane segment (TMR) of the receptor is preceded by putative O-linked sugar-binding 
domain (CHO). Modified from [29,42]. 
a-latrotoxin-binding activity from total rat brain ex- 
tracts [42]. 
Purified 16OK and 200K proteins give indistinguisha- 
ble peptide maps and show strong immune cross-reac- 
tivity , but they have a different carbohydrate composi- 
tion [37]. However, treatment with different glycosi- 
dases does not allow to reduce them to electrophoretic 
bands of the same size [42]. The 29K protein is not 
related to the 160K and 200K proteins since an anti- 
body against the 29K protein does not recognize any of 
the larger receptor components [40]. 
The information on internal peptide sequences ob- 
tained from a mixture of 166220K proteins was used 
to clone cDNAs representing a novel family of highly 
polymorphic cell surface membrane proteins which 
were named neurexins [42]. Neurexin mRNAs were 
only found in brain-related tissues [42], which perfectly 
correlates with the distribution of the a-latrotoxin re- 
ceptor [7]. At least three different neurexins exist [29]. 
Each of these have two forms (a, the longer; and /?, the 
shorter, sharing the same C-terminal region), which are 
probably the results of transcription from alternative 
promoters. In addition, all the neurexin cDNAs are 
alternatively spliced at least at 5 internal positions [42]. 
The a-latrotoxin receptor is probably a splice vari- 
ant of neurexin Ia. More than 20% of the neurexin Ia 
sequence is identical with the amino acid sequences of 
randomly distributed peptides derived from the purified 
receptor (Fig. 1). An antibody against a cytoplasmic 
C-terminal fragment of neurexin Ia immunoprecipitates 
the a-latiotoxin-binding activity [42]. However, at- 
tempts to express the functionally active receptor in 
COS cells have not so far been successful [42]. An expla- 
nation might be that the expression of a-latrotoxin- 
binding activity requires a specific combination of splic- 
ing at different sites of the neurexin Ia mRNA. 
Alternatively, there is a possibility that during the ex- 
pression in COS cells the protein does not undergo some 
specific posttranslational modification available only in 
neurons. Since oocytes injected with the total brain 
mRNA acquire the ability to respond to a-latrotoxin 
[43], this latter approach might become useful to iden- 
tify components necessary for proper a-latrotoxin re- 
ceptor expression. 
4. POSSIBLE FUNCTIONS OF THE a-LATRO- 
TOXIN RECEPTOR 
The a-latrotoxin receptor and, generally, neurexins 
are nerve-specific proteins, which are localized in pre- 
synaptic membranes [10,34,26,42]. What might be the 
physiological function of these proteins in the nerve 
terminal? a-Latrotoxin receptor is a membrane protein 
with only one transmembrane segment, a very short 
C-terminal cytoplasmic tail and an extensive N-terminal 
extracellular domain which is glycosylated and also 
contains three EGF-like repeats characteristic for ex- 
tracellular proteins (Fig. 1). These structural features 
make it unlikely that the receptor acts as an ion channel. 
There are six domains in the extracellular part of the 
receptor homologous to the laminin A G-domain re- 
peats, which are also found in agrin, perlecan, and slit 
[42]. These proteins are thought to be important in axon 
guidance and synaptogenesis. Thus, the extracellular 
part of the a-latrotoxin receptor was proposed to per- 
form a cell adhesion function in the nerve terminal 
[26,42]. The identification of cell structures interacting 
with the neurexin extracellular domain would be of help 
to verify this hypothesis. 
It seems likely that the function of the short cytoplas- 
mic tail of the neurexins is to complex with synaptic 
vesicles (Fig. 2) via the cytoplasmic domain of synapto- 
tagmin [41&l]. Synaptotagmin is a membrane-bound 
calcium- and lipid-binding glycoprotein, specifically lo- 
calized in synaptic vesicles (reviewed in [3]). Synapto- 
tagmin is implicated in neurotransmitter elease [45] 
and was proposed to act as a calcium sensor on the 
synaptic vesicle membrane [46]. 
Synaptotagmin co-purifies with the solubilized a-la- 
trotoxin receptor and this interaction is so specific that 
synaptotagmin can be purified in one step by affinity 
chromatography of the synaptic vesicles detergent ex- 
tract on a column with immobilized a-latrotoxin recep- 
tor [41]. Synaptotagmin binds to cytoplasmic domains 
of different neurexins, which appear to be highly con- 
served. A study with deletion mutants allowed to local- 
ize the synaptotagmin-binding site to the 40 amino acid 
residues of the C-terminus of neurexins [44]. 
Synaptotagmin was also reported to co-immunopre- 
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Fig. 2. Schematic model of the proposed organization of the a-latro- 
toxin receptor and other proteins at the nerve terminal. Based on the 
identified interactions of the a-latrotoxin receptor with synaptotagmin 
(SYT) [41] and 29K protein [40], synaptotagmin with syntaxin (SYN) 
and w-conotoxin receptor (Ca CHANNEL) 147,481, and syntaxin with 
20 S fusion particle (20 S) and synaptobrevin (SYB) [49], which is a 
target for tetanus and botulinum neurotoxins [6]. In vivo, the outlined 
interactions hould not necessarily occur simultaneously and may be 
controlled by levels of calcium, ATP, GTP, etc. 
cipitate with the w-conotoxin receptor [47,48], which is a 
presynaptic alcium channel protein, and with syntaxin 
[48], another presynaptic membrane protein implicated 
in membrane fusion [49]. Thus, the interactions involv- 
ing the a-latrotoxin receptor, or any other neurexins, 
may be important for the docking of synaptic vesicles 
at the release sites with proper positioning in relation to 
calcium channels, which induce neurotransmitter e- 
lease (Fig. 2). 
Synaptotagmin is phosphorylated by casein kinase II 
in vivo [50]. The calcium-dependent phosphorylation of 
synaptotagmin is specifically inhibited by the a-latro- 
toxin receptor [41]. Thus, it is possible that this phos- 
phorylation event is important for the regulation of a 
number of synaptic vesicles available for exocytosis as 
a function of amount of entered calcium. Such type of 
regulation may be involved in long-term potentiation 
events. 
5. CONCLUSIONS 
The use of a-latrotoxin as a tool has allowed to ob- 
tain important evidence supporting the vesicular model 
of neurotransmitter elease. The currently available 
data suggest hat there are two steps in toxin function- 
ing. The first step is the binding to the membrane-bound 
receptor, and the second one may involve the formation 
of a cation channel and/or the interaction with intracel- 
lular components, as a result of the translocation of 
a-latrotoxin across the cytoplasmic membrane. The 
structure of the a-latrotoxin receptor indicates that it 
may be a membrane protein important for cell recogni- 
tion in the synapse. It probably acts as a toxin acceptor 
and is not involved in transmembrane signalling. The 
intracellular targets of the toxin are yet to be identified. 
Undoubtedly, future studies will develop in both di- 
rections: to a further investigation of the mechanism of 
the a-latrotoxin function, which is important for un- 
derstanding neurotransmitter elease, and also to a 
study of the physiological function of the a-latrotoxin 
receptor and associated proteins. 
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